Connected Drug Delivery Devices Market Report 2026

The connected drug delivery devices market size has grown exponentially in recent years. It will grow from $9.27 billion in 2025 to $11.48 billion in 2026 at a compound annual growth rate (CAGR) of 23.8%. The growth in the historic period can be attributed to growing adoption of chronic disease management devices, increasing prevalence of diabetes and respiratory disorders, technological advancements in smart syringes and inhalers, rising healthcare digitization initiatives, increasing awareness about medication adherence.

The connected drug delivery devices market size is expected to see exponential growth in the next few years. It will grow to $27.02 billion in 2030 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to rising demand for remote patient monitoring, expansion of connected healthcare ecosystems, integration of ai-based predictive analytics, growth of wearable drug delivery devices, supportive government initiatives for digital health adoption. Major trends in the forecast period include personalized medication adherence monitoring, remote patient monitoring solutions, integration with electronic health records (ehr), data-driven dose optimization, real-time alerts and notifications.

The growing significance of remote patient monitoring is expected to drive the expansion of the connected drug delivery device market in the coming years. Remote patient monitoring is a healthcare delivery approach that leverages technology to track patient health and medical data from a distance. Connected drug delivery devices support RPM by allowing precise monitoring of medication usage and adherence, enabling timely interventions, and providing personalized care management. For instance, in May 2024, the Journal of Medical Internet Research, a Canada-based peer-reviewed journal, reported that 38.78% of US adults had used telehealth services in the past year. Therefore, the increasing importance of remote patient monitoring is fueling growth in the connected drug delivery device market.

Major companies in the connected drug delivery device market are focusing on introducing advanced, longer-lasting, and more integrated digital health solutions that improve treatment convenience, enhance monitoring accuracy, and enable seamless connectivity with automated therapy systems. For instance, in November 2025, Dexcom, a US-based healthcare company, announced the launch of its new G7 15 Day continuous glucose monitor in the U.S. on December 1, 2025, for adults with diabetes. Recently cleared by the FDA, the device will become the longest-wearing CGM available, offering up to 15.5 days of use with an improved accuracy MARD of 8%. At launch, it will be accessible through DME providers and covered for Medicare users. The updated sensor integrates with the iLet Bionic Pancreas, Omnipod 5, and soon Tandem pumps, while also supporting Dexcom’s new Smart Basal insulin optimization system. With fewer sensor replacements, a waterproof design, smartwatch connectivity, and simplified logging features, the G7 15 Day is designed to provide greater convenience and improved long-term glucose management.

In August 2023, Novo Nordisk A/S, a Denmark-based healthcare company, acquired BIOCORP Production SA for approximately €154 million (≈ $170 million). Through this acquisition, Novo Nordisk aimed to accelerate its digital drug-delivery strategy by incorporating Biocorp’s Bluetooth-enabled smart sensor technology to enhance its connected pen injector offerings. BIOCORP, a France-based company, designs and manufactures innovative delivery systems, including the Mallya Bluetooth-enabled add-on cap for insulin pens, which enables automatic dose logging and connectivity.

Major companies operating in the connected drug delivery devices market are Pfizer Inc., Johnson & Johnson, Abbott Laboratories, Medtronic PLC, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Phillips-Medisize Corporation, AptarGroup Inc., Dexcom Inc., West Pharmaceutical Services Inc., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed AG, Meridian Medical Technologies LLC, Propeller Health, Findair Sp. z.o.o, Omron Healthcare Co. Ltd, Omnicell Inc., BD Medical.

North America was the largest region in the connected drug delivery market in 2025. The regions covered in the connected drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the connected drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the connected drug delivery devices market by increasing costs of components such as sensors, connectivity modules, and data analytics software, creating supply chain disruptions. The impact is most pronounced in segments like smart inhalers, smart auto-injectors, and connected syringes, particularly in Asia-Pacific manufacturing hubs such as China and India. While tariffs have raised production costs, they have also encouraged manufacturers to localize production, diversify sourcing, and accelerate innovation, potentially improving cost efficiency and product reliability in the long term.

The connected drug delivery devices market research report is one of a series of new reports that provides connected drug delivery devices market statistics, including connected drug delivery devices industry global market size, regional shares, competitors with a connected drug delivery devices market share, detailed connected drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the connected drug delivery devices industry. This connected drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Connected drug delivery devices are smart pharmaceutical tools that use digital technology to monitor, manage, and control the administration of medications, improving adherence and patient outcomes. These devices can connect to the internet, enabling data sharing between patients and healthcare providers to track medication use, adjust dosages, and optimize treatment strategies.

The main types of connected drug delivery devices include standalone components, software, and integrated devices. Standalone components and software refer to hardware or software that can function independently or separately from the medical device with which it is used. These devices employ technologies such as Bluetooth, near-field communication (NFC), and others. The main routes of administration include parenteral and inhalational. They are applied in various areas, including asthma, chronic obstructive pulmonary disease, diabetes management, and others.

The connected drug delivery device market consists of revenues earned by entities by providing services such as medication reminders and alerts, dose tracking, data sharing, adjustable dosing, and integration with health records. The market value includes the value of related goods sold by the service provider or included within the service offering. The connected drug delivery device market also includes sales of smart inhalers, connected insulin pumps, smart pill dispensers, wearable drug delivery devices, and digital pills that are used in providing services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.